Key Developments: Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

4.29USD
28 Jul 2014
Price Change (% chg)

$-0.11 (-2.50%)
Prev Close
$4.40
Open
$4.38
Day's High
$4.39
Day's Low
$4.18
Volume
1,879,870
Avg. Vol
4,044,497
52-wk High
$6.95
52-wk Low
$2.24

Search Stocks

Latest Key Developments (Source: Significant Developments)

Novavax Inc announces exercise of option to purchase additional shares and closing of public offering
Wednesday, 11 Jun 2014 04:01pm EDT 

Novavax Inc:Announced the closing of the underwritten public offering priced on June 5.Issued 28,750,000 shares of its common stock, including 3,750,000 shares pursuant to the underwriters' option to purchase additional shares.Shares were issued at $4.00 per share resulting in total gross proceeds from this offering of $115,000,000, before deducting the underwriters discount and offering expenses.Intends to use a portion of the net proceeds from this offering to expand the clinical development of its RSV F-protein nanoparticle vaccine candidate through the initiation of a Phase 2 clinical trial in elderly subjects later this year.  Full Article

Novavax Inc prices public offering of common stock
Thursday, 5 Jun 2014 08:55pm EDT 

Novavax Inc:Says that it has priced an underwritten public offering of 25 mln shares of common stock at a price to the public of $4.00 per share for gross proceeds of about $100 mln.Expects to receive net proceeds, after deducting the underwriting discount, of about $94 mln from the offering.Expects to grant to underwriters a 30-day option to purchase up to additional 3.75 mln shares of its common stock.Intends to use net proceeds from offering for general corporate purposes, advancement of its clinical-stage vaccine candidates and its pre-clinical research programs, manufacturing and process development activities, capital expenditures and other strategic purposes.Expects to close offering on or about June 11.Citigroup and JP Morgan are acting as joint book-running managers of offering.Piper Jaffray & Co. will act as Lead Manager and FBR and Ladenburg Thalmann & Co. Inc. as co-managers.  Full Article

Novavax announces proposed public offering of common stock
Wednesday, 4 Jun 2014 04:01pm EDT 

Novavax Inc:Intends to offer to sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.Intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of its common stock.Citigroup and JP Morgan are acting as joint book-running managers of the offering.  Full Article

Novavax announces independent registered public accounting firm change - Form 8-K
Wednesday, 30 Apr 2014 05:23pm EDT 

Novavax Inc:On April 24, Audit Committee selected Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec. 31, 2014, subject to completion of standard client acceptance procedures.Also on April 24, Grant Thornton LLP was notified that they would be dismissed as auditors upon completion of the work relating to company’s interim financial statements for period ending March 31on quarterly report on Form 10-Q.  Full Article

Novavax announces positive top-line data from dose-confirmatory phase 2 clinical trial of RSV vaccine candidate in women of childbearing age
Monday, 28 Apr 2014 04:13pm EDT 

Novavax Inc:Says positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase 2 clinical trial in women of childbearing age.Randomized, blinded, placebo-controlled Phase 2 study was designed to evaluate the immunogenicity and safety of multiple formulations of Novavax' RSV-F protein nanoparticle vaccine adjuvanted with aluminum phosphate.Primary outcome of the trial was safety and immune response (measured by levels of serum IgG antibody specific for the F protein).These top-line data relate to the safety and immunogenicity over the 91-day period following first immunization and support Novavax' maternal immunization strategy.  Full Article

Novavax Inc announces extension of contract with Department of Health and Human Services, Biomedical Advanced Research and Development Authority
Thursday, 27 Feb 2014 04:15pm EST 

Novavax Inc:Announces execution of contract modification to extend base period of performance of its current contract with U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA).Contract is for advanced development of Novavax' recombinant seasonal and pandemic influenza vaccines.Novavax and BARDA have agreed to amend agreement to allow Novavax to continue to access remainder of the $97 million in base period funding through September.These funds will support upcoming Phase 2 trial for H7N9 vaccine candidate with Matrix-M, and activities relating to quadrivalent seasonal influenza vaccine.BARDA has ability to dedicate up to $79 million in additional funds to support Novavax' later-stage development of these vaccines.  Full Article

Novavax Inc announces continuation of RSV vaccine partnership with PATH
Monday, 13 Jan 2014 08:00am EST 

Novavax Inc:Says continuation of their partnership with PATH to develop Novavax' RSV (respiratory syncytial virus) vaccine for maternal immunization.Says under this amendment, PATH will provide Novavax about $3.5 mln in funding to support the ongoing Phase II dose-confirmatory clinical trial in women of childbearing age, initiated in October 2013.Says under this partnership, Novavax and PATH will also initiate planning activities for clinical development of the vaccine in low-resource countries.Says under this partnership, PATH and Novavax may elect to continue to collaborate on additional clinical trials to further develop Novavax' RSV vaccine for maternal immunization in low-resource countries.  Full Article

Novavax Inc Completes $100 Million Public Offering Of Common Stock
Friday, 27 Sep 2013 11:29am EDT 

Novavax Inc announced the closing of its previously announced underwritten public offering of 31,846,950 shares of its common stock, including 4,153,950 shares of common stock that were issued upon the exercise in full of the over-allotment option granted to the underwriters. The shares were sold at the public offering price of $3.14 per share, resulting in total gross proceeds of $100 million dollars. Novavax will receive net proceeds, after deducting underwriting discounts and commissions and offering expenses, of approximately $94.6 million from the offering. Lazard Capital Markets LLC acted as the sole book-running manager for the offering, with Piper Jaffray & Co. and Wedbush PacGrow Life Sciences acting as co-lead managers and Burrill Securities LLC acting as co-manager.  Full Article

Novavax Inc Prices Public Offering of Common Stock
Tuesday, 24 Sep 2013 08:02am EDT 

Novavax Inc (Novavax) announced that it has priced an underwritten public offering of 27,693,000 shares of common stock at a price of $3.14 per share, the closing price of the stock on the previous day, for gross proceeds of approximately $87.0 million. Novavax expects to receive net proceeds, after deducting the underwriting discount, of approximately $82.6 million from the offering. In connection with this offering, Novavax granted the underwriters a 30-day overallotment option to purchase up to an additional 4,153,950 shares of its common stock. Novavax intends to use the net proceeds of the offering for general corporate purposes, the advancement of its clinical-stage vaccine candidates and its pre-clinical research programs. The offering is expected to close on or about September 27, 2013, subject to the satisfaction of customary closing conditions. Lazard Capital Markets LLC is acting as the sole book-running manager for the offering. Piper Jaffray & Co. and Wedbush PacGrow Life Sciences are acting as co-lead managers and Burrill Securities LLC is acting as co-manager for the offering.  Full Article

Novavax Inc Initiates Compulsory Acquisition Procedure for Remaining Shares in Isconova AB; Isconova AB Applies for Delisting
Wednesday, 21 Aug 2013 01:00pm EDT 

Isconova AB announced that Novavax, Inc., which controls approximately 97.4% of the shares and votes in Isconova AB and warrants representing 100% of warrants in Isconova AB, has initiated a compulsory acquisition procedure regarding the remaining shares in Isconova AB. Based on the above, the board of directors of Isconova AB considers that it is no longer justified for Isconova AB to remain listed and has therefore, on August 21, 2013, resolved to request that the shares of Isconova AB are delisted from NASDAQ OMX First North Premier. Last day for trading in the Isconova AB shares on NASDAQ OMX First North Premier will preliminary be two weeks following NASDAQ OMX’s acceptance of Isconova AB’s request for delisting, and will be announced as soon as Isconova AB has received notice thereof from NASDAQ OMX.  Full Article

Search Stocks